Choice of first line treatment and survival in metastatic colorectal cancer – a retrospective analysis

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter A. Oliveira
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors A. Oliveira, L. Bretes, I. Furtado
  • Centro Hospitalar do Algarve - Faro, Faro, Portugal, /


Selection of first line treatment for patients with metastatic colorectal cancer (mCRC) is based on tumour and patient related factors. The wide and increasingly use of targeting agents in this setting are proven to be beneficial in first line treatment. Increasing evidence suggests that this first line treatment is of great importance and its impact is being studied in prospective studies. In this retrospective analysis, we aimed to analyze the first treatment used and its potential impact on overall survival (OS).